Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Status:
Completed
Trial end date:
2013-06-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in
subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after
multiple therapies including rituximab or radioimmunotherapy. The investigational drug will
be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every
4 weeks.